Bill · S. 4692· Senate(119-S-4692)
Homeopathic Drug Product Safety, Quality, and Transparency Act
- Introduced
- 6/4/2026
- Last activity
- 6/4/2026 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Sponsored by
- Tommy Tuberville
- Cosponsors
- - 1 - 0
- Introduced
- In Committee
What this bill would do
This bill sets up specific rules for how homeopathic drug products are regulated in the United States. It creates a new definition for homeopathic drugs and exempts them from standard new drug approval applications. The legislation requires the Secretary to issue final rules on good manufacturing practices and labeling requirements within three years. It also establishes a Homeopathic Drug Product Advisory Committee to provide advice and recommendations on these products. Finally, the bill updates misbranding rules for dietary supplements, drugs, and cosmetics that use homeopathic terms improperly.
Yes· 3 of 4
Would business owners be better off under this?+3
Business owners in the homeopathic manufacturing industry benefit from a defined legal and regulatory framework.
Does this make it easier to run a small business?+3
The bill provides regulatory clarity and a distinct statutory framework for homeopathic product manufacturers, many of which are small businesses.
Does this make what the government does easier for the public to see?+2
The legislation introduces specific labeling requirements and creates an advisory committee, enhancing transparency for consumers and regulators.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Advisory Representation: Section 3(b)(1), adding Section 503E(g), establishes a Homeopathic Drug Product Advisory Committee that includes practitioners, manufacturers, educators, and consumers. This ensures that various community perspectives are represented when the government makes decisions about these products.
-
Clear Product Labeling: Section 3(b)(1), adding Section 503E(f), requires retail homeopathic products to display specific statements regarding FDA evaluation and traditional uses. This gives consumers clear information about what the products are and how they are regulated.
-
Contaminant and Defect Testing: Section 3(b)(1), adding Section 503E(e), maintains the requirement that finished homeopathic products must be tested for contaminants and defects. This helps protect the health and safety of the people who use these products.
Potential Negative Impacts for People
-
Exemption from Standard Approvals: Section 3(b)(1), adding Section 503E(b), exempts homeopathic drug products from standard premarket approval requirements under section 505 of the Federal Food, Drug, and Cosmetic Act. This means these products will not go through the same rigorous new drug approval process that regular medicines must follow before being sold.
-
Exemption from Certain Laboratory Testing: Section 3(b)(1), adding Section 503E(e)(1), exempts finished homeopathic drug products from the requirement for laboratory determinations of the identity and strength of each active ingredient. This could make it harder to verify the exact active contents of a finished product.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Business Owners+3
- Economy And Finance
- Improves Small Business Support+3
- Governance And Ideology
- Improves Government Transparency+2
- Healthcare
- Improves Healthcare Access+2
- 6/4/2026
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 1 Cosponsor added.
- Introduced in Senate
Mike LeeRepublican · Utah